;PMID: 8971143
;source_file_931.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..222] = [t:48..222]
;2)section:[e:226..287] = [t:226..287]
;3)section:[e:291..385] = [t:291..385]
;4)sentence:[e:389..691] = [t:389..691]
;5)sentence:[e:692..971] = [t:692..971]
;6)sentence:[e:972..1116] = [t:972..1116]
;7)sentence:[e:1117..1260] = [t:1117..1260]
;8)sentence:[e:1261..1425] = [t:1261..1425]
;9)sentence:[e:1426..1740] = [t:1426..1740]
;10)sentence:[e:1741..1861] = [t:1741..1861]
;11)sentence:[e:1862..2086] = [t:1862..2086]
;12)sentence:[e:2087..2257] = [t:2087..2257]
;13)section:[e:2261..2305] = [t:2261..2305]

;section 0 Span:0..42
;Drug Metab Dispos. 1996 Dec;24(12):1362-8.
(SEC
  (FRAG (NNP:[0..4] Drug) (NNP:[5..10] Metab) (NNP:[11..17] Dispos)
        (,:[17..18] .) (CD:[19..23] 1996) (NNP:[24..27] Dec) (::[27..28] ;)
        (CD:[28..30] 24) (-LRB-:[30..31] -LRB-) (CD:[31..33] 12)
        (-RRB-:[33..34] -RRB-) (::[34..35] :) (CD:[35..39] 1362) (::[39..40] -)
        (CD:[40..41] 8) (.:[41..42] .)))

;sentence 1 Span:48..222
;Catalysis of the dealkylation/debenzylation of phenoxazone ethers by
;hemoglobin  in the absence of peroxides: implications for investigations of
;embryonic  biotransformation.
;[95..113]:substance:"phenoxazone ethers"
;[117..127]:substance:"hemoglobin"
;[147..156]:substance:"peroxides"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[48..57] Catalysis))
      (PP (IN:[58..60] of)
        (NP
          (NP (DT:[61..64] the) (NN:[65..77] dealkylation) (SYM:[77..78] /)
              (NN:[78..91] debenzylation))
          (PP (IN:[92..94] of)
            (NP (NN:[95..106] phenoxazone) (NNS:[107..113] ethers)))))
      (PP (IN:[114..116] by)
        (NP (NN:[117..127] hemoglobin)))
      (PP-LOC (IN:[129..131] in)
        (NP
          (NP (DT:[132..135] the) (NN:[136..143] absence))
          (PP (IN:[144..146] of)
            (NP (NNS:[147..156] peroxides))))))
    (::[156..157] :)
    (NP
      (NP (NNS:[158..170] implications))
      (PP (IN:[171..174] for)
        (NP
          (NP (NNS:[175..189] investigations))
          (PP (IN:[190..192] of)
            (NP (JJ:[193..202] embryonic) (NN:[204..221] biotransformation))))))
    (.:[221..222] .)))

;section 2 Span:226..287
;Juchau MR, Chapman DE, Yang HY, Lee QP, Namkung MJ, Hinds TR.
(SEC
  (FRAG (NNP:[226..232] Juchau) (NNP:[233..235] MR) (,:[235..236] ,)
        (NNP:[237..244] Chapman) (NNP:[245..247] DE) (,:[247..248] ,)
        (NNP:[249..253] Yang) (NNP:[254..256] HY) (,:[256..257] ,)
        (NNP:[258..261] Lee) (NNP:[262..264] QP) (,:[264..265] ,)
        (NNP:[266..273] Namkung) (NNP:[274..276] MJ) (,:[276..277] ,)
        (NNP:[278..283] Hinds) (NNP:[284..286] TR) (.:[286..287] .)))

;section 3 Span:291..385
;Department of Pharmacology, School of Medicine, University of Washington, 
;Seattle 98195, USA.
(SEC
  (FRAG (NNP:[291..301] Department) (IN:[302..304] of)
        (NNP:[305..317] Pharmacology) (,:[317..318] ,) (NNP:[319..325] School)
        (IN:[326..328] of) (NNP:[329..337] Medicine) (,:[337..338] ,)
        (NNP:[339..349] University) (IN:[350..352] of)
        (NNP:[353..363] Washington) (,:[363..364] ,) (NNP:[366..373] Seattle)
        (CD:[374..379] 98195) (,:[379..380] ,) (NNP:[381..384] USA)
        (.:[384..385] .)))

;sentence 4 Span:389..691
;Investigations of catalysis of the O-dealkylation and O-debenzylation of 
;phenoxazone (resorufin) ethers in human and rodent embryonic tissue
;homogenates  indicated that, with few exceptions, each conceptal tissue
;investigated  contained enzymes capable of catalyzing each of the reactions
;under study.
;[463..493]:substance:"phenoxazone (resorufin) ethers"
;[531..542]:substance:"homogenates"
;[627..634]:substance:"enzymes"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[389..403] Investigations))
      (PP (IN:[404..406] of)
        (NP
          (NP (NN:[407..416] catalysis))
          (PP (IN:[417..419] of)
            (NP
              (NP (DT:[420..423] the) (NN:[424..438] O-dealkylation)
                  (CC:[439..442] and) (NN:[443..458] O-debenzylation))
              (PP (IN:[459..461] of)
                (NP
                  (NML
                    (NML (NN:[463..474] phenoxazone))
                    (NML (-LRB-:[475..476] -LRB-) (NN:[476..485] resorufin)
                         (-RRB-:[485..486] -RRB-)))
                  (NNS:[487..493] ethers)))))))
      (PP-LOC (IN:[494..496] in)
        (NP
          (NP (JJ:[497..502] human)
            (ADJP-1 (-NONE-:[502..502] *P*))
            (NML-2 (-NONE-:[502..502] *P*)))
          (CC:[503..506] and)
          (NP (NN:[507..513] rodent)
            (ADJP-1 (JJ:[514..523] embryonic))
            (NML-2 (NN:[524..530] tissue) (NNS:[531..542] homogenates))))))
    (VP (VBD:[544..553] indicated)
      (SBAR (IN:[554..558] that) (,:[558..559] ,)
        (S
          (PP (IN:[560..564] with)
            (NP (JJ:[565..568] few) (NNS:[569..579] exceptions)))
          (,:[579..580] ,)
          (NP-SBJ
            (NP (DT:[581..585] each) (JJ:[586..595] conceptal)
                (NN:[596..602] tissue))
            (VP (VBN:[603..615] investigated)
              (NP (-NONE-:[615..615] *))))
          (VP (VBD:[617..626] contained)
            (NP
              (NP (NNS:[627..634] enzymes))
              (ADJP (JJ:[635..642] capable)
                (PP (IN:[643..645] of)
                  (S-NOM
                    (NP-SBJ (-NONE-:[645..645] *))
                    (VP (VBG:[646..656] catalyzing)
                      (NP
                        (NP (DT:[657..661] each))
                        (PP (IN:[662..664] of)
                          (NP
                            (NP (DT:[665..668] the) (NNS:[669..678] reactions))
                            (PP (IN:[679..684] under)
                              (NP (NN:[685..690] study)))))))))))))))
    (.:[690..691] .)))

;sentence 5 Span:692..971
;All  observable reactions exhibited NADPH dependence and strong inhibition by
;carbon  monoxide, ketoconazole, alternate electron acceptors, and by hypoxic
;incubation  conditions; but, they were not strongly inhibited by several
;other classical  cytochrome P450 (P450) inhibitors.
;[728..733]:substance:"NADPH"
;[770..786]:substance:"carbon  monoxide"
;[788..800]:substance:"ketoconazole"
;[937..952]:cyp450:"cytochrome P450"
;[954..958]:cyp450:"P450"
;[960..970]:substance:"inhibitors"
(SENT
  (S
    (S
      (NP-SBJ (DT:[692..695] All) (JJ:[697..707] observable)
              (NNS:[708..717] reactions))
      (VP (VBD:[718..727] exhibited)
        (NP
          (NP (NN:[728..733] NADPH) (NN:[734..744] dependence))
          (CC:[745..748] and)
          (NP
            (NP (JJ:[749..755] strong) (NN:[756..766] inhibition))
            (PP
              (PP (IN:[767..769] by)
                (NP
                  (NP
                     (NN:[770..776] carbon) (NN:[778..786] monoxide)
                    (NML-1 (-NONE-:[786..786] *P*)))
                  (,:[786..787] ,)
                  (NP (NN:[788..800] ketoconazole)
                    (NML-1 (-NONE-:[800..800] *P*)))
                  (,:[800..801] ,)
                  (NP (JJ:[802..811] alternate) (NN:[812..820] electron)
                    (NML-1 (NNS:[821..830] acceptors)))))
              (,:[830..831] ,) (CC:[832..835] and)
              (PP (IN:[836..838] by)
                (NP (JJ:[839..846] hypoxic) (NN:[847..857] incubation)
                    (NNS:[859..869] conditions))))))))
    (::[869..870] ;) (CC:[871..874] but) (,:[874..875] ,)
    (S
      (NP-SBJ-2 (PRP:[876..880] they))
      (VP (VBD:[881..885] were) (RB:[886..889] not)
        (ADVP (RB:[890..898] strongly))
        (VP (VBN:[899..908] inhibited)
          (NP-2 (-NONE-:[908..908] *))
          (PP (IN:[909..911] by)
            (NP-LGS (JJ:[912..919] several) (JJ:[920..925] other)
                    (JJ:[926..935] classical)
              (NML
                (NML (NN:[937..947] cytochrome) (NN:[948..952] P450))
                (NML (-LRB-:[953..954] -LRB-) (NN:[954..958] P450)
                     (-RRB-:[958..959] -RRB-)))
              (NNS:[960..970] inhibitors))))))
    (.:[970..971] .)))

;sentence 6 Span:972..1116
;Cyanide, azide, superoxide  dismutase/catalase, and glutathione/glutathione
;peroxidase each also failed to  inhibit the reactions significantly.
;[972..979]:substance:"Cyanide"
;[981..986]:substance:"azide"
;[988..1009]:substance:"superoxide  dismutase"
;[988..998]...[1010..1018]:substance:"superoxide"..."catalase"
;[1024..1035]...[1048..1058]:substance:"glutathione"..."peroxidase"
;[1036..1058]:substance:"glutathione peroxidase"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[972..979] Cyanide))
      (,:[979..980] ,)
      (NP (NN:[981..986] azide))
      (,:[986..987] ,)
      (NP
         (NN:[988..998] superoxide) (NN:[1000..1009] dismutase)
        (SYM:[1009..1010] /) (NN:[1010..1018] catalase))
      (,:[1018..1019] ,) (CC:[1020..1023] and)
      (NP
        (NP (NN:[1024..1035] glutathione))
        (SYM:[1035..1036] /)
        (NP (NN:[1036..1047] glutathione) (NN:[1048..1058] peroxidase))))
    (DT:[1059..1063] each)
    (ADVP (RB:[1064..1068] also))
    (VP (VBD:[1069..1075] failed)
      (S
        (NP-SBJ-1 (-NONE-:[1075..1075] *))
        (VP (TO:[1076..1078] to)
          (VP (VB:[1080..1087] inhibit)
            (NP (DT:[1088..1091] the) (NNS:[1092..1101] reactions))
            (ADVP-MNR (RB:[1102..1115] significantly))))))
    (.:[1115..1116] .)))

;sentence 7 Span:1117..1260
;Subcellular fractionation experiments  revealed that cytosolic fractions
;contained a preponderance of the observable  monooxygenase activities.
;[1235..1248]:substance:"monooxygenase"
(SENT
  (S
    (NP-SBJ (JJ:[1117..1128] Subcellular) (NN:[1129..1142] fractionation)
            (NNS:[1143..1154] experiments))
    (VP (VBD:[1156..1164] revealed)
      (SBAR (IN:[1165..1169] that)
        (S
          (NP-SBJ (JJ:[1170..1179] cytosolic) (NNS:[1180..1189] fractions))
          (VP (VBD:[1190..1199] contained)
            (NP
              (NP (DT:[1200..1201] a) (NN:[1202..1215] preponderance))
              (PP (IN:[1216..1218] of)
                (NP (DT:[1219..1222] the) (JJ:[1223..1233] observable)
                    (NN:[1235..1248] monooxygenase)
                    (NNS:[1249..1259] activities))))))))
    (.:[1259..1260] .)))

;sentence 8 Span:1261..1425
;Attempts to identify components responsible for the  cytosolic catalytic
;activity indicated that cytosolic nitric oxide synthases did  not contribute
;significantly.
;[1368..1390]:substance:"nitric oxide synthases"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1261..1269] Attempts))
      (SBAR
        (WHNP (-NONE-:[1269..1269] 0))
        (S
          (NP-SBJ (-NONE-:[1269..1269] *))
          (VP (TO:[1270..1272] to)
            (VP (VB:[1273..1281] identify)
              (NP
                (NP (NNS:[1282..1292] components))
                (ADJP (JJ:[1293..1304] responsible)
                  (PP (IN:[1305..1308] for)
                    (NP (DT:[1309..1312] the) (JJ:[1314..1323] cytosolic)
                        (JJ:[1324..1333] catalytic) (NN:[1334..1342] activity))))))))))
    (VP (VBD:[1343..1352] indicated)
      (SBAR (IN:[1353..1357] that)
        (S
          (NP-SBJ (JJ:[1358..1367] cytosolic)
            
            (NML (JJ:[1368..1374] nitric) (NN:[1375..1380] oxide))
            (NNS:[1381..1390] synthases))
          (VP (VBD:[1391..1394] did) (RB:[1396..1399] not)
            (VP (VB:[1400..1410] contribute)
              (ADVP-MNR (RB:[1411..1424] significantly)))))))
    (.:[1424..1425] .)))

;sentence 9 Span:1426..1740
;Column fractionation of the cytosol indicated that  significant catalytic
;activity coeluted with fractions containing hemoglobin  (Hgb), and
;experiments with purified Hgb as enzyme source showed that Hgb would 
;catalyze all reactions under study at very slow rates in the absence of added
; reductases or peroxides.
;[1544..1554]:substance:"hemoglobin"
;[1557..1560]:substance:"Hgb"
;[1593..1596]:substance:"Hgb"
;[1600..1606]:substance:"enzyme"
;[1626..1629]:substance:"Hgb"
;[1716..1726]:substance:"reductases"
;[1730..1739]:substance:"peroxides"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[1426..1432] Column) (NN:[1433..1446] fractionation))
        (PP (IN:[1447..1449] of)
          (NP (DT:[1450..1453] the) (NN:[1454..1461] cytosol))))
      (VP (VBD:[1462..1471] indicated)
        (SBAR (IN:[1472..1476] that)
          (S
            (NP-SBJ (JJ:[1478..1489] significant) (JJ:[1490..1499] catalytic)
                    (NN:[1500..1508] activity))
            (VP (VBD:[1509..1517] coeluted)
              (PP-CLR (IN:[1518..1522] with)
                (NP
                  (NP (NNS:[1523..1532] fractions))
                  (VP (VBG:[1533..1543] containing)
                    (NP
                      (NP (NN:[1544..1554] hemoglobin))
                      (NP (-LRB-:[1556..1557] -LRB-) (NN:[1557..1560] Hgb)
                          (-RRB-:[1560..1561] -RRB-)))))))))))
    (,:[1561..1562] ,) (CC:[1563..1566] and)
    (S
      (NP-SBJ
        (NP (NNS:[1567..1578] experiments))
        (PP (IN:[1579..1583] with)
          (NP (VBN:[1584..1592] purified) (NN:[1593..1596] Hgb)))
        (PP (IN:[1597..1599] as)
          (NP (NN:[1600..1606] enzyme) (NN:[1607..1613] source))))
      (VP (VBD:[1614..1620] showed)
        (SBAR (IN:[1621..1625] that)
          (S
            (NP-SBJ (NN:[1626..1629] Hgb))
            (VP (MD:[1630..1635] would)
              (VP (VB:[1637..1645] catalyze)
                (NP
                  (NP (DT:[1646..1649] all) (NNS:[1650..1659] reactions))
                  (PP (IN:[1660..1665] under)
                    (NP (NN:[1666..1671] study))))
                (PP (IN:[1672..1674] at)
                  (NP
                    (ADJP (RB:[1675..1679] very) (JJ:[1680..1684] slow))
                    (NNS:[1685..1690] rates)))
                (PP-LOC (IN:[1691..1693] in)
                  (NP
                    (NP (DT:[1694..1697] the) (NN:[1698..1705] absence))
                    (PP (IN:[1706..1708] of)
                      (NP
                        (NP
                          (ADJP-1 (VBN:[1709..1714] added))
                          (NNS:[1716..1726] reductases))
                        (CC:[1727..1729] or)
                        (NP
                          (ADJP-1 (-NONE-:[1729..1729] *P*))
                          (NNS:[1730..1739] peroxides))))))))))))
    (.:[1739..1740] .)))

;sentence 10 Span:1741..1861
;Additions of either reductases or peroxides, however,  resulted in marked
;increases in rates of Hgb-catalyzed reactions.
;[1761..1771]:substance:"reductases"
;[1775..1784]:substance:"peroxides"
;[1837..1840]:substance:"Hgb"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1741..1750] Additions))
      (PP (IN:[1751..1753] of)
        (NP (CC:[1754..1760] either) (NNS:[1761..1771] reductases)
            (CC:[1772..1774] or) (NNS:[1775..1784] peroxides))))
    (,:[1784..1785] ,)
    (ADVP (RB:[1786..1793] however))
    (VP (,:[1793..1794] ,) (VBD:[1796..1804] resulted)
      (PP-CLR (IN:[1805..1807] in)
        (NP
          (NP (JJ:[1808..1814] marked) (NNS:[1815..1824] increases))
          (PP (IN:[1825..1827] in)
            (NP
              (NP (NNS:[1828..1833] rates))
              (PP (IN:[1834..1836] of)
                (NP
                  (ADJP (NN:[1837..1840] Hgb) (HYPH:[1840..1841] -)
                        (VBN:[1841..1850] catalyzed))
                  (NNS:[1851..1860] reactions))))))))
    (.:[1860..1861] .)))

;sentence 11 Span:1862..2086
;Further  investigations strongly suggested that virtually all dealkylation or
; debenzylation of phenoxazone ethers catalyzed by embryonic cytosolic
;fractions  could be accounted for by the presence of Hgb in those fractions.
;[1958..1976]:substance:"phenoxazone ethers"
;[2063..2066]:substance:"Hgb"
(SENT
  (S
    (NP-SBJ (JJ:[1862..1869] Further) (NNS:[1871..1885] investigations))
    (ADVP-MNR (RB:[1886..1894] strongly))
    (VP (VBD:[1895..1904] suggested)
      (SBAR (IN:[1905..1909] that)
        (S
          (NP-SBJ-1
            (NP
              (NP
                (QP (RB:[1910..1919] virtually) (DT:[1920..1923] all))
                (NN:[1924..1936] dealkylation) (CC:[1937..1939] or)
                 (NN:[1941..1954] debenzylation))
              (PP (IN:[1955..1957] of)
                (NP (NN:[1958..1969] phenoxazone) (NNS:[1970..1976] ethers))))
            (VP (VBN:[1977..1986] catalyzed)
              (NP (-NONE-:[1986..1986] *))
              (PP (IN:[1987..1989] by)
                (NP-LGS (JJ:[1990..1999] embryonic) (JJ:[2000..2009] cytosolic)
                        (NNS:[2010..2019] fractions)))))
          (VP (MD:[2021..2026] could)
            (VP (VB:[2027..2029] be)
              (VP (VBN:[2030..2039] accounted)
                (PP-CLR (IN:[2040..2043] for)
                  (NP-1 (-NONE-:[2043..2043] *)))
                (PP (IN:[2044..2046] by)
                  (NP-LGS
                    (NP (DT:[2047..2050] the) (NN:[2051..2059] presence))
                    (PP (IN:[2060..2062] of)
                      (NP (NN:[2063..2066] Hgb)))
                    (PP-LOC (IN:[2067..2069] in)
                      (NP (DT:[2070..2075] those) (NNS:[2076..2085] fractions)))))))))))
    (.:[2085..2086] .)))

;sentence 12 Span:2087..2257
;Conceptal  microsomal fractions, however, exhibited definitive,
;P450-dependent  monooxygenase activities attributable to specific individual,
;identifiable P450  isoforms.
;[2151..2155]:cyp450:"P450"
;[2167..2180]:substance:"monooxygenase"
;[2242..2256]:cyp450:"P450  isoforms"
(SENT
  (S
    (NP-SBJ (JJ:[2087..2096] Conceptal) (JJ:[2098..2108] microsomal)
            (NNS:[2109..2118] fractions))
    (,:[2118..2119] ,)
    (ADVP (RB:[2120..2127] however))
    (VP (,:[2127..2128] ,) (VBD:[2129..2138] exhibited)
      (NP
        (NP (JJ:[2139..2149] definitive) (,:[2149..2150] ,)
          (ADJP (NN:[2151..2155] P450) (HYPH:[2155..2156] -)
                (JJ:[2156..2165] dependent))
          (NN:[2167..2180] monooxygenase) (NNS:[2181..2191] activities))
        (ADJP (JJ:[2192..2204] attributable)
          (PP (TO:[2205..2207] to)
            (NP (JJ:[2208..2216] specific) (JJ:[2217..2227] individual)
                (,:[2227..2228] ,) (JJ:[2229..2241] identifiable)
               (NN:[2242..2246] P450) (NNS:[2248..2256] isoforms))))))
    (.:[2256..2257] .)))

;section 13 Span:2261..2305
;PMID: 8971143 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2261..2265] PMID) (::[2265..2266] :) (CD:[2267..2274] 8971143)
        (NN:[2275..2276] -LSB-) (NNP:[2276..2282] PubMed) (::[2283..2284] -)
        (NN:[2285..2292] indexed) (IN:[2293..2296] for)
        (NNP:[2297..2304] MEDLINE) (-RRB-:[2304..2305] -RSB-)))
